11 March 2022
Kalydeco – application for widening access to go to Pharamc’s Respiratory Subcommittee.
In August 2021, a member of our CF community made a “consumer” application to Pharmac to have the criteria for access to the Vertex CF modulator therapy Kalydeco widened. The application sought approval to have additional mutations added to Pharmac’s existing access criteria. The details of the application can be found here.
Pharmac has advised CFNZ that it intends that the application be considered at the meeting of its Respiratory Subcommittee to be held in late April. CFNZ submitted in support of this application late last year. We also referred Pharmac to the substantial package of material submitted in support of Vertex’s Trikafta application, much of which is also relevant to Kalydeco.
Fingers crossed there is a positive outcome from the Respiratory Subcommittee – Pharmac’s expert clinical advisers. CFNZ’s goal is for every Kiwi with CF to have access to a modulator therapy that would benefit them and we’ll do all we can to push for the widening of access to Kalydeco, alongside Trikafta. And a big thank you to the “consumer” who made this application.